Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Travere Therapeutics price target lowered to $41 from $44 at Piper Sandler » 07:46
03/13/23
03/13
07:46
03/13/23
07:46
TVTX

Travere Therapeutics

$20.75 /

-0.4 (-1.89%)

, CALT

Calliditas Therapeutics

$16.84 /

-0.46 (-2.66%)

Piper Sandler lowered the…

Piper Sandler lowered the firm's price target on Travere Therapeutics (TVTX) to $41 from $44 and keeps an Overweight rating on the shares. The analyst believes Calliditas Therapeutics' (CALT) two-year estimated glomerular filtration rate data for Tarpeyo in immunoglobulin A nephropathy is a positive readthrough for Travere, with the company's upcoming PROTECT eGFR data for Filspari expected in Q4. Piper cites dilution from Travere's secondary offering for the target drop.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$20.75 /

-0.4 (-1.89%)

CALT Calliditas Therapeutics
$16.84 /

-0.46 (-2.66%)

TVTX Travere Therapeutics
$20.75 /

-0.4 (-1.89%)

02/28/23 Guggenheim
Travere Therapeutics initiated with a Buy, $37 price target at Guggenheim
02/28/23 Guggenheim
Travere Therapeutics initiated with a Buy at Guggenheim
02/28/23 Canaccord
Travere Therapeutics price target lowered to $42 from $44 at Canaccord
02/22/23 Wells Fargo
Wells Fargo downgrades Cerevel on lack of catalysts until 2024
CALT Calliditas Therapeutics
$16.84 /

-0.46 (-2.66%)

02/28/23 Guggenheim
Calliditas Therapeutics initiated with a Neutral, $18 price target at Guggenheim
02/28/23 Guggenheim
Calliditas Therapeutics initiated with a Neutral at Guggenheim
02/24/23 Citi
Calliditas Therapeutics price target raised to $79 from $76 at Citi
06/16/22 Kepler Cheuvreux
Calliditas Therapeutics initiated with a Buy at Kepler Cheuvreux
TVTX Travere Therapeutics
$20.75 /

-0.4 (-1.89%)

  • 01
    Mar
TVTX Travere Therapeutics
$20.75 /

-0.4 (-1.89%)

Syndicate
Travere Therapeutics 8.275M share Spot Secondary priced at $21.00 » 05:58
03/01/23
03/01
05:58
03/01/23
05:58
TVTX

Travere Therapeutics

$22.17 /

+0.415 (+1.91%)

The deal size was…

The deal size was increased to $200M in common stock from $175M in common stock. Jefferies, JPMorgan, BofA and SVB Securities acted as joint book running managers for the offering.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$22.17 /

+0.415 (+1.91%)

TVTX Travere Therapeutics
$22.17 /

+0.415 (+1.91%)

02/28/23 Guggenheim
Travere Therapeutics initiated with a Buy, $37 price target at Guggenheim
02/28/23 Guggenheim
Travere Therapeutics initiated with a Buy at Guggenheim
02/28/23 Canaccord
Travere Therapeutics price target lowered to $42 from $44 at Canaccord
02/22/23 Wells Fargo
Wells Fargo downgrades Cerevel on lack of catalysts until 2024
TVTX Travere Therapeutics
$22.17 /

+0.415 (+1.91%)

  • 01
    Mar
TVTX Travere Therapeutics
$22.17 /

+0.415 (+1.91%)

Initiation
Travere Therapeutics initiated with a Buy, $37 price target at Guggenheim » 16:39
02/28/23
02/28
16:39
02/28/23
16:39
TVTX

Travere Therapeutics

$22.17 /

+0.415 (+1.91%)

As previously reported,…

As previously reported, Guggenheim initiated coverage of Travere Therapeutics with a Buy rating and $37 price target. While the firm expects it will take time for the company to gain traction with their recently FDA-approved endothelin receptor antagonist Filspari, they expect physicians to gain increasing comfort with the product over time in both immunoglobulin A nephropathy, or IgAN, and focal segmental glomerulosclerosis, or FSGS. The firm estimates peak Filspari U.S. annual sales across both indications to exceed $1.8Bn in 2032.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$22.17 /

+0.415 (+1.91%)

TVTX Travere Therapeutics
$22.17 /

+0.415 (+1.91%)

02/28/23 Guggenheim
Travere Therapeutics initiated with a Buy at Guggenheim
02/28/23 Canaccord
Travere Therapeutics price target lowered to $42 from $44 at Canaccord
02/22/23 Wells Fargo
Wells Fargo downgrades Cerevel on lack of catalysts until 2024
02/22/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
TVTX Travere Therapeutics
$22.17 /

+0.415 (+1.91%)

  • 01
    Mar
TVTX Travere Therapeutics
$22.17 /

+0.415 (+1.91%)

Initiation
Travere Therapeutics initiated with a Buy at Guggenheim » 16:17
02/28/23
02/28
16:17
02/28/23
16:17
TVTX

Travere Therapeutics

$22.17 /

+0.415 (+1.91%)

Guggenheim analyst Vamil…

Guggenheim analyst Vamil Divan initiated coverage of Travere Therapeutics with a Buy rating and $37 price target.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$22.17 /

+0.415 (+1.91%)

TVTX Travere Therapeutics
$22.17 /

+0.415 (+1.91%)

02/28/23 Canaccord
Travere Therapeutics price target lowered to $42 from $44 at Canaccord
02/22/23 Wells Fargo
Wells Fargo downgrades Cerevel on lack of catalysts until 2024
02/22/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
02/21/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
TVTX Travere Therapeutics
$22.17 /

+0.415 (+1.91%)

  • 01
    Mar
TVTX Travere Therapeutics
$22.17 /

+0.415 (+1.91%)

Recommendations
Travere Therapeutics price target lowered to $42 from $44 at Canaccord » 07:35
02/28/23
02/28
07:35
02/28/23
07:35
TVTX

Travere Therapeutics

$21.76 /

-0.56 (-2.51%)

Canaccord analyst Edward…

Canaccord analyst Edward Nash lowered the firm's price target on Travere Therapeutics to $42 from $44 and keeps a Buy rating on the shares. The analyst said the target decrease is solely related to an increase in SG&A assumptions in 2023 and out years.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$21.76 /

-0.56 (-2.51%)

TVTX Travere Therapeutics
$21.76 /

-0.56 (-2.51%)

02/22/23 Wells Fargo
Wells Fargo downgrades Cerevel on lack of catalysts until 2024
02/22/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
02/21/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
02/21/23 Evercore ISI
Travere Therapeutics price target raised to $36 from $30 at Evercore ISI
TVTX Travere Therapeutics
$21.76 /

-0.56 (-2.51%)

  • 01
    Mar
TVTX Travere Therapeutics
$21.76 /

-0.56 (-2.51%)

Syndicate
Travere Therapeutics announces $175M common stock offering » 16:40
02/27/23
02/27
16:40
02/27/23
16:40
TVTX

Travere Therapeutics

$21.76 /

-0.56 (-2.51%)

Travere Therapeutics…

Travere Therapeutics announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175M of its common stock. Jefferies, J.P. Morgan, BofA Securities and SVB Securities are acting as the joint book-running managers for the offering.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$21.76 /

-0.56 (-2.51%)

TVTX Travere Therapeutics
$21.76 /

-0.56 (-2.51%)

02/22/23 Wells Fargo
Wells Fargo downgrades Cerevel on lack of catalysts until 2024
02/22/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
02/21/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
02/21/23 Evercore ISI
Travere Therapeutics price target raised to $36 from $30 at Evercore ISI
TVTX Travere Therapeutics
$21.76 /

-0.56 (-2.51%)

TVTX Travere Therapeutics
$21.76 /

-0.56 (-2.51%)

Earnings
Travere Therapeutics reports Q4 EPS ($1.03), consensus ($1.07) » 16:16
02/23/23
02/23
16:16
02/23/23
16:16
TVTX

Travere Therapeutics

$21.92 /

+1.08 (+5.18%)

Reports Q4 revenue…

Reports Q4 revenue $55.87M, consensus $53.01M. "2022 was a foundational year for Travere. We demonstrated clinical expertise with the advancement of our development programs, reached new patients with our approved products, and prepared our organization for a new phase of growth to deliver new medicines to rare disease patients," said Eric Dube, Ph.D., chief executive officer of Travere Therapeutics. "Most importantly, our accomplishments in 2022 led to the recent accelerated approval of FILSPARI for the reduction of proteinuria in patients with IgAN, the first FDA approval from our development pipeline of therapies targeting rare diseases with limited or no treatment options. Our teams began calling on prescribers on February 20th and we are pleased with the early reception to education on FILSPARI's superior proteinuria reduction compared to irbesartan and its well-defined safety profile. In addition to remaining focused on a successful U.S. launch of FILSPARI in 2023, we are continuing to advance our programs with a number of exciting milestones ahead. In the second quarter, we look forward to two-year data from the ongoing DUPLEX Study of sparsentan in FSGS, and later in the year we expect a review decision on the CMA application for sparsentan for the treatment of IgAN in Europe. We also anticipate additional data from our novel pegtibatinase program for HCU and the potential initiation of a Phase 3 program this year. We take great pride in our progress to date and are honored to provide life-changing treatments to patients with rare disease."

ShowHide Related Items >><<
TVTX Travere Therapeutics
$21.92 /

+1.08 (+5.18%)

TVTX Travere Therapeutics
$21.92 /

+1.08 (+5.18%)

02/22/23 Wells Fargo
Wells Fargo downgrades Cerevel on lack of catalysts until 2024
02/22/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
02/21/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
02/21/23 Evercore ISI
Travere Therapeutics price target raised to $36 from $30 at Evercore ISI
TVTX Travere Therapeutics
$21.92 /

+1.08 (+5.18%)

TVTX Travere Therapeutics
$21.92 /

+1.08 (+5.18%)

Downgrade
Wells Fargo downgrades Cerevel on lack of catalysts until 2024 » 16:46
02/22/23
02/22
16:46
02/22/23
16:46
CERE

Cerevel Therapeutics

$26.73 /

-4.39 (-14.11%)

, TVTX

Travere Therapeutics

$20.84 /

-0.55 (-2.57%)

, XENE

Xenon Pharmaceuticals

$37.10 /

+0.53 (+1.45%)

Wells Fargo analyst Mohit…

Wells Fargo analyst Mohit Bansal downgraded Cerevel Therapeutics (CERE) to Equal Weight from Overweight with a price target of $30, down from $38. The darigabat timeline shift removes a key 2023 catalyst and the stock could be range-bound due to a lack of catalysts until 2024, the analyst tells investors in a research note. The firm now favors shares of Travere Therapeutics (TVTX) and Xenon Pharmaceuticals (XENE) for smaller cap biotech exposure. Cerevel highlighted external factors such as staffing challenges and slow enrollment in clinical trials as the reasons for darigabat delay, Wells points out. It also believes the risk/reward for the emraclidine Phase 2 data "looks less compelling" given that the Street already assigns a high probability of success.

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$37.10 /

+0.53 (+1.45%)

TVTX Travere Therapeutics
$20.84 /

-0.55 (-2.57%)

CERE Cerevel Therapeutics
$26.73 /

-4.39 (-14.11%)

CERE Cerevel Therapeutics
$26.73 /

-4.39 (-14.11%)

02/22/23 Wells Fargo
Cerevel Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
12/20/22 Cantor Fitzgerald
Cerevel Therapeutics price target raised to $46 from $41 at Cantor Fitzgerald
12/19/22 Wells Fargo
Wells Fargo keeps Overweight on Cerevel after Phase 1 emraclidine trial results
12/06/22 JPMorgan
Cerevel Therapeutics price target lowered to $40 from $49 at JPMorgan
TVTX Travere Therapeutics
$20.84 /

-0.55 (-2.57%)

02/22/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
02/21/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
02/21/23 Evercore ISI
Travere Therapeutics price target raised to $36 from $30 at Evercore ISI
02/21/23 Piper Sandler
Travere Therapeutics price target raised to $46 from $42 at Piper Sandler
XENE Xenon Pharmaceuticals
$37.10 /

+0.53 (+1.45%)

01/04/23 JPMorgan
Xenon Pharmaceuticals price target raised to $54 from $52 at JPMorgan
12/14/22 Goldman Sachs
Xenon Pharmaceuticals initiated with a Buy at Goldman Sachs
12/12/22 TD Cowen
Xenon Pharmaceuticals initiated with an Outperform at Cowen on XEN1101 optimism
12/12/22 TD Cowen
Xenon Pharmaceuticals initiated with an Outperform at Cowen
XENE Xenon Pharmaceuticals
$37.10 /

+0.53 (+1.45%)

TVTX Travere Therapeutics
$20.84 /

-0.55 (-2.57%)

CERE Cerevel Therapeutics
$26.73 /

-4.39 (-14.11%)

  • 12
    Aug
  • 23
    Jun
XENE Xenon Pharmaceuticals
$37.10 /

+0.53 (+1.45%)

TVTX Travere Therapeutics
$20.84 /

-0.55 (-2.57%)

CERE Cerevel Therapeutics
$26.73 /

-4.39 (-14.11%)

Recommendations
Travere Therapeutics price target raised to $44 from $40 at Canaccord » 07:38
02/22/23
02/22
07:38
02/22/23
07:38
TVTX

Travere Therapeutics

$21.39 /

+3.57 (+20.03%)

Canaccord analyst Edward…

Canaccord analyst Edward Nash raised the firm's price target on Travere Therapeutics to $44 from $40 and keeps a Buy rating on the shares. The analyst sad his target increase was based solely on the announced pricing for Filspari which received accelerated approval from the FDA.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$21.39 /

+3.57 (+20.03%)

TVTX Travere Therapeutics
$21.39 /

+3.57 (+20.03%)

02/21/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
02/21/23 Evercore ISI
Travere Therapeutics price target raised to $36 from $30 at Evercore ISI
02/21/23 Piper Sandler
Travere Therapeutics price target raised to $46 from $42 at Piper Sandler
02/21/23 Wedbush
Wedbush upgrades Travere Therapeutics to Outperform, raises target to $30
TVTX Travere Therapeutics
$21.39 /

+3.57 (+20.03%)

TVTX Travere Therapeutics
$21.39 /

+3.57 (+20.03%)

Over a month ago
On The Fly
What You Missed On Wall Street On Tuesday » 16:15
02/21/23
02/21
16:15
02/21/23
16:15
HD

Home Depot

$295.54 /

-22.55 (-7.09%)

, META

Meta Platforms

$172.10 /

-0.82 (-0.47%)

, TECK

Teck Resources

$43.26 /

-0.865 (-1.96%)

, DIS

Disney

$102.06 /

-3.165 (-3.01%)

, MSFT

Microsoft

$252.68 /

-5.27 (-2.04%)

, NVDA

Nvidia

$206.43 /

-7.49 (-3.50%)

, ATVI

Activision Blizzard

$77.02 /

-0.52 (-0.67%)

, VIR

Vir Biotechnology

$26.95 /

+1.22 (+4.74%)

, NSC

Norfolk Southern

$224.65 /

-3.45 (-1.51%)

, AN

AutoNation

$143.32 /

-14.06 (-8.93%)

, DOCU

DocuSign

$59.61 /

-4.995 (-7.73%)

, RMAX

RE/MAX Holdings

$18.66 /

-1.03 (-5.23%)

, CS

Credit Suisse

$2.92 /

-0.105 (-3.47%)

, TSM

TSMC

$87.65 /

-2.37 (-2.63%)

, TSLA

Tesla

$197.35 /

-10.96 (-5.26%)

, T

AT&T

$19.20 /

-0.25 (-1.29%)

, TVTX

Travere Therapeutics

$21.39 /

+3.57 (+20.03%)

, HLX

Helix Energy

$8.53 /

+0.905 (+11.87%)

, APLS

Apellis

$58.42 /

+2.925 (+5.27%)

, ATNM

Actinium Pharmaceuticals

$11.37 /

-2.315 (-16.92%)

, BCRX

BioCryst

$8.63 /

-1.56 (-15.31%)

, DAN

Dana

$15.53 /

-3.315 (-17.60%)

, WMT

Walmart

$147.32 /

+0.83 (+0.57%)

, ADTN

Adtran

$16.55 /

-0.445 (-2.62%)

, EXPD

Expeditors

$105.20 /

-6.22 (-5.58%)

, KLXE

KLX Energy

$12.28 /

-0.305 (-2.42%)

, MDT

Medtronic

$85.53 /

+0.705 (+0.83%)

Get caught up quickly on…

ShowHide Related Items >><<
WMT Walmart
$147.32 /

+0.83 (+0.57%)

VIR Vir Biotechnology
$26.95 /

+1.22 (+4.74%)

TVTX Travere Therapeutics
$21.39 /

+3.57 (+20.03%)

TSM TSMC
$87.65 /

-2.37 (-2.63%)

TSLA Tesla
$197.35 /

-10.96 (-5.26%)

TECK Teck Resources
$43.26 /

-0.865 (-1.96%)

T AT&T
$19.20 /

-0.25 (-1.29%)

RMAX RE/MAX Holdings
$18.66 /

-1.03 (-5.23%)

NVDA Nvidia
$206.43 /

-7.49 (-3.50%)

NSC Norfolk Southern
$224.65 /

-3.45 (-1.51%)

MSFT Microsoft
$252.68 /

-5.27 (-2.04%)

META Meta Platforms
$172.10 /

-0.82 (-0.47%)

MDT Medtronic
$85.53 /

+0.705 (+0.83%)

HLX Helix Energy
$8.53 /

+0.905 (+11.87%)

HD Home Depot
$295.54 /

-22.55 (-7.09%)

EXPD Expeditors
$105.20 /

-6.22 (-5.58%)

DOCU DocuSign
$59.61 /

-4.995 (-7.73%)

DIS Disney
$102.06 /

-3.165 (-3.01%)

DAN Dana
$15.53 /

-3.315 (-17.60%)

CS Credit Suisse
$2.92 /

-0.105 (-3.47%)

BCRX BioCryst
$8.63 /

-1.56 (-15.31%)

ATVI Activision Blizzard
$77.02 /

-0.52 (-0.67%)

ATNM Actinium Pharmaceuticals
$11.37 /

-2.315 (-16.92%)

APLS Apellis
$58.42 /

+2.925 (+5.27%)

AN AutoNation
$143.32 /

-14.06 (-8.93%)

ADTN Adtran
$16.55 /

-0.445 (-2.62%)

HD Home Depot
$295.54 /

-22.55 (-7.09%)

02/22/23 Barclays
Home Depot price target lowered to $310 from $323 at Barclays
02/21/23 Baird
Home Depot price target lowered to $340 from $360 at Baird
02/17/23 Evercore ISI
Home Depot added to 'Tactical Underperform' list at Evercore ISI
02/15/23 Piper Sandler
Home Depot price target lowered to $300 from $320 at Piper Sandler
META Meta Platforms
$172.10 /

-0.82 (-0.47%)

02/21/23 BofA
BofA sees 12M potential subscriber opportunity for Meta Verified
02/13/23 BofA
BofA sees room for additional efficiencies at Meta
02/10/23 Tigress Financial
Meta Platforms price target raised to $285 from $260 at Tigress Financial
02/08/23 Loop Capital
Meta Platforms price target raised to $188 from $165 at Loop Capital
TECK Teck Resources
$43.26 /

-0.865 (-1.96%)

02/16/23 Canaccord
Teck Resources upgraded to Buy at Canaccord on coal spin potential
02/16/23 Canaccord
Teck Resources upgraded to Buy from Hold at Canaccord
02/13/23 National Bank
Teck Resources price target raised to C$70 from C$65 at National Bank
02/01/23 RBC Capital
Teck Resources price target raised to C$64 from C$62 at RBC Capital
DIS Disney
$102.06 /

-3.165 (-3.01%)

02/13/23 JPMorgan
Disney reinstated with an Overweight at JPMorgan
02/13/23 Citi
Disney price target lowered to $130 from $145 at Citi
02/09/23 Loop Capital
Disney price target raised to $130 from $120 at Loop Capital
02/09/23 BofA
Disney price target raised to $135 from $115 at BofA
MSFT Microsoft
$252.68 /

-5.27 (-2.04%)

02/16/23 Deutsche Bank
Deutsche upgrades Activision to Buy, says best risk/reward in gaming
02/13/23 Morgan Stanley
Morgan Stanley sees 5 quarters of accelerating EPS growth at Microsoft after Q2
02/13/23 BofA
BofA starts Okta at Underperform with 'no positive catalysts in sight'
02/10/23 Roth MKM
Activision Blizzard price target lowered to $88 from $95 at Roth MKM
NVDA Nvidia
$206.43 /

-7.49 (-3.50%)

02/21/23 BMO Capital
Nvidia price target raised to $240 from $210 at BMO Capital
02/21/23 Stifel
Nvidia price target raised to $207 from $175 at Stifel
02/21/23 Morgan Stanley
Nvidia price target raised to $246 from $175 at Morgan Stanley
02/17/23 Oppenheimer
Nvidia price target raised to $250 from $225 at Oppenheimer
ATVI Activision Blizzard
$77.02 /

-0.52 (-0.67%)

02/16/23 Deutsche Bank
Activision Blizzard upgraded to Buy from Hold at Deutsche Bank
02/08/23 Morgan Stanley
Activision Blizzard risk/reward 'highly compelling,' says Morgan Stanley
VIR Vir Biotechnology
$26.95 /

+1.22 (+4.74%)

02/21/23 Goldman Sachs
Vir Biotechnology upgraded to Buy from Neutral at Goldman Sachs
01/27/23 Morgan Stanley
Vir Biotechnology upgraded to Equal Weight from Underweight at Morgan Stanley
09/14/22 SVB Securities
SVB Securities bullish on Vir Biotechnology, initiates with an Outperform
09/14/22 SVB Securities
Vir Biotechnology initiated with an Outperform at SVB Securities
NSC Norfolk Southern
$224.65 /

-3.45 (-1.51%)

02/21/23 Wolfe Research
Norfolk Southern upgraded to Outperform from Peer Perform at Wolfe Research
02/14/23 BofA
Norfolk Southern derailment EPS impact likely minimal given insurance, says BofA
01/26/23 BMO Capital
Norfolk Southern price target raised to $250 from $245 at BMO Capital
01/26/23 RBC Capital
Norfolk Southern price target lowered to $244 from $253 at RBC Capital
AN AutoNation
$143.32 /

-14.06 (-8.93%)

02/21/23 Guggenheim
AutoNation price target raised to $181 from $169 at Guggenheim
02/21/23 Wells Fargo
AutoNation price target raised to $154 from $126 at Wells Fargo
02/21/23 JPMorgan
AutoNation downgraded to Underweight from Neutral at JPMorgan
01/17/23 Morgan Stanley
AutoNation downgraded to Underweight from Equal Weight at Morgan Stanley
DOCU DocuSign
$59.61 /

-4.995 (-7.73%)

02/21/23 UBS
DocuSign downgraded to Sell from Neutral at UBS
02/16/23 MoffettNathanson
DocuSign price target lowered to $50 from $63 at MoffettNathanson
01/05/23 Jefferies
DocuSign upgraded to Buy from Hold at Jefferies
01/05/23 Piper Sandler
DocuSign price target raised to $55 from $50 at Piper Sandler
RMAX RE/MAX Holdings
$18.66 /

-1.03 (-5.23%)

02/21/23 Stephens
RE/MAX Holdings downgraded to Equal Weight at Stephens on lack of catalysts
02/21/23 Stephens
RE/MAX Holdings downgraded to Equal Weight from Overweight at Stephens
03/02/22 JonesResearch
RE/MAX Holdings initiated with a Buy at JonesTrading
02/28/22 Keefe Bruyette
RE/MAX Holdings price target lowered to $35 from $37 at Keefe Bruyette
CS Credit Suisse
$2.92 /

-0.105 (-3.47%)

02/16/23 Citi
Credit Suisse downgraded at Citi on franchise erosion and poor visibility
02/16/23 Citi
Credit Suisse downgraded to Neutral from Buy at Citi
02/13/23 Kepler Cheuvreux
Kepler downgrades Credit Suisse to Reduce on earnings concerns
02/13/23 Kepler Cheuvreux
Credit Suisse downgraded to Reduce from Hold at Kepler Cheuvreux
TSM TSMC
$87.65 /

-2.37 (-2.63%)

01/27/23 BofA
Intel price target lowered to $25 from $28 at BofA
01/12/23 Needham
Impinj price target raised to $130 from $120 at Needham
01/10/23 Morgan Stanley
TSMC named a 'Catalyst Driven Idea' at Morgan Stanley
11/18/22 Erste Group
TSMC upgraded to Buy from Hold at Erste Group
TSLA Tesla
$197.35 /

-10.96 (-5.26%)

02/22/23 Bernstein
Pricing among important issues into Tesla's analyst day, says Bernstein
02/21/23 Wells Fargo
Wells Fargo says Tesla possible lithium play would secure capacity
02/20/23 Wells Fargo
Tesla risks 'clearly remain' after self driving recall, says Wells Fargo
02/16/23 Gordon Haskett
Natixis doesn't hold 190M share Tesla stake, admits error, says Gordon Haskett
T AT&T
$19.20 /

-0.25 (-1.29%)

02/15/23 Wells Fargo
Wells Fargo downgrades Dycom to Equal Weight, lowers price target to $88
02/07/23 LightShed Partners
AT&T downgraded to Neutral from Buy at LightShed Partners
02/06/23 MoffettNathanson
T-Mobile downgraded at MoffettNathanson amid 'great deceleration'
01/26/23 TD Cowen
AT&T price target raised to $25 from $24 at Cowen
TVTX Travere Therapeutics
$21.39 /

+3.57 (+20.03%)

02/21/23 Canaccord
Travere Therapeutics price target raised to $44 from $40 at Canaccord
02/21/23 Evercore ISI
Travere Therapeutics price target raised to $36 from $30 at Evercore ISI
02/21/23 Piper Sandler
Travere Therapeutics price target raised to $46 from $42 at Piper Sandler
02/21/23 Wedbush
Wedbush upgrades Travere Therapeutics to Outperform, raises target to $30
HLX Helix Energy
$8.53 /

+0.905 (+11.87%)

01/03/23 BTIG
Helix Energy named Top Pick for first half of 2023 at BTIG
10/26/22 BTIG
Helix Energy upgraded to Buy from Neutral at BTIG
10/07/22 Piper Sandler
Helix Energy assumed with an Overweight at Piper Sandler
07/27/22 Evercore ISI
Helix Energy upgraded to Outperform at Evercore ISI as second half ramp begins
APLS Apellis
$58.42 /

+2.925 (+5.27%)

02/21/23 H.C. Wainwright
H.C. Wainwright says Belite Bio opportunity intact despite GA treatment approval
02/21/23 BofA
Apellis price target raised to $115 from $79 at BofA
02/21/23 Stifel
Apellis price target raised to $75 from $65 at Stifel
02/21/23 Baird
Apellis price target raised to $105 from $90 at Baird
ATNM Actinium Pharmaceuticals
$11.37 /

-2.315 (-16.92%)

02/21/23 William Blair
Actinium downgraded despite positive data at William Blair
02/21/23 William Blair
Actinium Pharmaceuticals downgraded to Market Perform from Outperform at William Blair
10/31/22 Maxim
Actinium Pharmaceuticals price target raised to $35 from $25 at Maxim
10/31/22 B. Riley
Actinium Pharmaceuticals price target raised to $18 from $16 at B. Riley
BCRX BioCryst
$8.63 /

-1.56 (-15.31%)

01/09/23 Piper Sandler
BioCryst reports preliminary Q4 miss for Orladeyo, says Piper Sandler
12/16/22 Barclays
BioCryst price target lowered to $10 from $12 at Barclays
12/15/22 Oppenheimer
Oppenheimer keeps Perform on BioCryst after discontinuation of BCX9930 program
12/15/22 TD Cowen
Cowen says full sale of BioCryst 'potentially now even more likely'
DAN Dana
$15.53 /

-3.315 (-17.60%)

02/22/23 Barclays
Dana price target lowered to $18 from $20 at Barclays
02/14/23 Barclays
Barclays starts autos and mobility sector, says Tesla stands out
02/14/23 Barclays
Dana initiated with an Equal Weight at Barclays
01/19/23 Deutsche Bank
Deutsche Bank keeps Hold on Dana, raises price target to $16
WMT Walmart
$147.32 /

+0.83 (+0.57%)

02/17/23 Evercore ISI
Walmart added to 'Tactical Outperform' list at Evercore ISI
02/15/23 TD Cowen
Walmart price target raised to $180 from $175 at Cowen
02/14/23 Roth MKM
Walmart to get more aggressive on food pricing and market share, says Roth MKM
02/10/23 Gordon Haskett
Gordon Haskett upgrades Walmart to Accumulate on price leadership
ADTN Adtran
$16.55 /

-0.445 (-2.62%)

09/26/22 Loop Capital
Adtran upgraded to Buy from Hold at Loop Capital
09/26/22 Loop Capital
Adtran upgraded to Buy from Hold at Loop Capital
09/13/22 WestPark Capital
Adtran initiated with a Hold at WestPark Capital
07/14/22 Needham
Adtran initiated with a Buy at Needham
EXPD Expeditors
$105.20 /

-6.22 (-5.58%)

01/06/23 TD Cowen
Expeditors price target lowered to $108 from $122 at Cowen
11/22/22 Wells Fargo
Wells Fargo downgrades Expeditors to Underweight with $95 price target
11/22/22 Wells Fargo
Expeditors downgraded to Underweight from Equal Weight at Wells Fargo
11/09/22 Susquehanna
Expeditors price target lowered to $95 from $110 at Susquehanna
KLXE KLX Energy
$12.28 /

-0.305 (-2.42%)

12/22/22 EF Hutton
KLX Energy assumed with a Buy at EF Hutton
11/21/22 EF Hutton
KLX Energy initiated with a Buy at EF Hutton
11/18/22 Piper Sandler
KLX Energy price target raised to $19 from $10 at Piper Sandler
10/07/22 Piper Sandler
KLX Energy assumed with a Neutral at Piper Sandler
MDT Medtronic
$85.53 /

+0.705 (+0.83%)

01/31/23 Bernstein
Edwards Lifesciences downgraded to Underperform from Outperform at Bernstein
01/24/23 Mizuho
Medtronic price target lowered to $95 from $100 at Mizuho
01/09/23 RBC Capital
Medtronic downgraded to Sector Perform from Outperform at RBC Capital
11/30/22 Wells Fargo
Medtronic price target lowered to $77 from $82 at Wells Fargo
WMT Walmart
$147.32 /

+0.83 (+0.57%)

VIR Vir Biotechnology
$26.95 /

+1.22 (+4.74%)

TVTX Travere Therapeutics
$21.39 /

+3.57 (+20.03%)

TSM TSMC
$87.65 /

-2.37 (-2.63%)

TSLA Tesla
$197.35 /

-10.96 (-5.26%)

TECK Teck Resources
$43.26 /

-0.865 (-1.96%)

T AT&T
$19.20 /

-0.25 (-1.29%)

RMAX RE/MAX Holdings
$18.66 /

-1.03 (-5.23%)

NVDA Nvidia
$206.43 /

-7.49 (-3.50%)

NSC Norfolk Southern
$224.65 /

-3.45 (-1.51%)

MSFT Microsoft
$252.68 /

-5.27 (-2.04%)

META Meta Platforms
$172.10 /

-0.82 (-0.47%)

MDT Medtronic
$85.53 /

+0.705 (+0.83%)

KLXE KLX Energy
$12.28 /

-0.305 (-2.42%)

HLX Helix Energy
$8.53 /

+0.905 (+11.87%)

HD Home Depot
$295.54 /

-22.55 (-7.09%)

EXPD Expeditors
$105.20 /

-6.22 (-5.58%)

DOCU DocuSign
$59.61 /

-4.995 (-7.73%)

DIS Disney
$102.06 /

-3.165 (-3.01%)

DAN Dana
$15.53 /

-3.315 (-17.60%)

CS Credit Suisse
$2.92 /

-0.105 (-3.47%)

BCRX BioCryst
$8.63 /

-1.56 (-15.31%)

ATVI Activision Blizzard
$77.02 /

-0.52 (-0.67%)

AN AutoNation
$143.32 /

-14.06 (-8.93%)

ADTN Adtran
$16.55 /

-0.445 (-2.62%)

  • 24
    Mar
WMT Walmart
$147.32 /

+0.83 (+0.57%)

VIR Vir Biotechnology
$26.95 /

+1.22 (+4.74%)

TSM TSMC
$87.65 /

-2.37 (-2.63%)

TSLA Tesla
$197.35 /

-10.96 (-5.26%)

TECK Teck Resources
$43.26 /

-0.865 (-1.96%)

T AT&T
$19.20 /

-0.25 (-1.29%)

NVDA Nvidia
$206.43 /

-7.49 (-3.50%)

NSC Norfolk Southern
$224.65 /

-3.45 (-1.51%)

MSFT Microsoft
$252.68 /

-5.27 (-2.04%)

META Meta Platforms
$172.10 /

-0.82 (-0.47%)

MDT Medtronic
$85.53 /

+0.705 (+0.83%)

HD Home Depot
$295.54 /

-22.55 (-7.09%)

DIS Disney
$102.06 /

-3.165 (-3.01%)

DAN Dana
$15.53 /

-3.315 (-17.60%)

CS Credit Suisse
$2.92 /

-0.105 (-3.47%)

ATVI Activision Blizzard
$77.02 /

-0.52 (-0.67%)

WMT Walmart
$147.32 /

+0.83 (+0.57%)

VIR Vir Biotechnology
$26.95 /

+1.22 (+4.74%)

TVTX Travere Therapeutics
$21.39 /

+3.57 (+20.03%)

TSM TSMC
$87.65 /

-2.37 (-2.63%)

TSLA Tesla
$197.35 /

-10.96 (-5.26%)

TECK Teck Resources
$43.26 /

-0.865 (-1.96%)

T AT&T
$19.20 /

-0.25 (-1.29%)

RMAX RE/MAX Holdings
$18.66 /

-1.03 (-5.23%)

NVDA Nvidia
$206.43 /

-7.49 (-3.50%)

NSC Norfolk Southern
$224.65 /

-3.45 (-1.51%)

MSFT Microsoft
$252.68 /

-5.27 (-2.04%)

META Meta Platforms
$172.10 /

-0.82 (-0.47%)

MDT Medtronic
$85.53 /

+0.705 (+0.83%)

HLX Helix Energy
$8.53 /

+0.905 (+11.87%)

HD Home Depot
$295.54 /

-22.55 (-7.09%)

DOCU DocuSign
$59.61 /

-4.995 (-7.73%)

DIS Disney
$102.06 /

-3.165 (-3.01%)

CS Credit Suisse
$2.92 /

-0.105 (-3.47%)

BCRX BioCryst
$8.63 /

-1.56 (-15.31%)

ATNM Actinium Pharmaceuticals
$11.37 /

-2.315 (-16.92%)

APLS Apellis
$58.42 /

+2.925 (+5.27%)

ADTN Adtran
$16.55 /

-0.445 (-2.62%)

WMT Walmart
$147.32 /

+0.83 (+0.57%)

TSM TSMC
$87.65 /

-2.37 (-2.63%)

TSLA Tesla
$197.35 /

-10.96 (-5.26%)

TECK Teck Resources
$43.26 /

-0.865 (-1.96%)

T AT&T
$19.20 /

-0.25 (-1.29%)

NVDA Nvidia
$206.43 /

-7.49 (-3.50%)

NSC Norfolk Southern
$224.65 /

-3.45 (-1.51%)

MSFT Microsoft
$252.68 /

-5.27 (-2.04%)

META Meta Platforms
$172.10 /

-0.82 (-0.47%)

MDT Medtronic
$85.53 /

+0.705 (+0.83%)

HLX Helix Energy
$8.53 /

+0.905 (+11.87%)

HD Home Depot
$295.54 /

-22.55 (-7.09%)

EXPD Expeditors
$105.20 /

-6.22 (-5.58%)

DOCU DocuSign
$59.61 /

-4.995 (-7.73%)

DIS Disney
$102.06 /

-3.165 (-3.01%)

CS Credit Suisse
$2.92 /

-0.105 (-3.47%)

ATVI Activision Blizzard
$77.02 /

-0.52 (-0.67%)

ATNM Actinium Pharmaceuticals
$11.37 /

-2.315 (-16.92%)

APLS Apellis
$58.42 /

+2.925 (+5.27%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.